ACIP vote, more FDA turnover; Introducing Endpoints Signal; ARCH, Parker Institute building next cancer bet; and morenews2025-12-06T11:00:06+00:00December 6th, 2025|Endpoints News|
Makary’s user fee comments; M&A activity stays hot; A new use for prime editing; and morenews2025-11-22T11:00:03+00:00November 22nd, 2025|Endpoints News|
Inside the Metsera bidding war; PD-(L)1xVEGF bispecific race heats up; Pazdur tapped as next CDER head; and morenews2025-11-15T11:00:13+00:00November 15th, 2025|Endpoints News|
White House unveils MFN deals; Metsera saga ends; Q3 earnings updates; and morenews2025-11-08T11:00:57+00:00November 8th, 2025|Endpoints News|
Novo makes a play for Metsera; This week’s other big deal; Earnings in full swing; and morenews2025-11-01T10:00:55+00:00November 1st, 2025|Endpoints News|
Tracking pharma’s flights to DC; Novo’s boardroom drama; #ESMO25 recap from Berlin; and morenews2025-10-25T10:00:49+00:00October 25th, 2025|Endpoints News|
John Carroll’s Q3 analysis; Q&A with a Nobel Prize winner; Excellergy’s allergy plan; and morenews2025-10-18T10:00:50+00:00October 18th, 2025|Endpoints News|
Meet this year’s Women in Biopharma; Peter Marks goes to Eli Lilly; Bob Langer startup launches; and morenews2025-10-11T10:00:36+00:00October 11th, 2025|Endpoints News|
Pfizer’s ‘most favored nation’ deal; Metsera’s obesity data; Takeda stops cell therapy work; and morenews2025-10-04T10:00:39+00:00October 4th, 2025|Endpoints News|
Pfizer’s GLP-1 acquisition; Trump’s tariff threat; Scholar Rock gets a CRL; and morenews2025-09-27T10:00:08+00:00September 27th, 2025|Endpoints News|
